Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Cash from Operations (2016 - 2025)

Fate Therapeutics' Cash from Operations history spans 14 years, with the latest figure at 23314000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations rose 16.13% year-over-year to 23314000.0; the TTM value through Dec 2025 reached 106084000.0, up 13.66%, while the annual FY2025 figure was 106084000.0, 13.66% up from the prior year.
  • Cash from Operations reached 23314000.0 in Q4 2025 per FATE's latest filing, up from 24374000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 23314000.0 in Q4 2025 to a low of 75389000.0 in Q4 2022.
  • Average Cash from Operations over 5 years is 38614950.0, with a median of 32828000.0 recorded in 2024.
  • Peak YoY movement for Cash from Operations: plummeted 240.17% in 2021, then skyrocketed 55.33% in 2023.
  • A 5-year view of Cash from Operations shows it stood at 70293000.0 in 2021, then dropped by 7.25% to 75389000.0 in 2022, then surged by 51.4% to 36637000.0 in 2023, then rose by 24.12% to 27799000.0 in 2024, then increased by 16.13% to 23314000.0 in 2025.
  • Per Business Quant, the three most recent readings for FATE's Cash from Operations are 23314000.0 (Q4 2025), 24374000.0 (Q3 2025), and 24587000.0 (Q2 2025).